TScan Therapeutics to Connect with Investors at Major Conferences
TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology firm focused on developing T cell receptor (TCR)-engineered T cell therapies for cancer treatment, has announced its participation in several key investor conferences.
Upcoming Conferences
The first event is the Morgan Stanley 22nd Annual Global Healthcare Conference, where a fireside chat is scheduled for Thursday at 8:30 a.m. ET. This will take place at the New York Marriott Marquis.
H.C. Wainwright 26th Annual Global Investment Conference
Following that, TScan will take part in the H.C. Wainwright 26th Annual Global Investment Conference. This presentation is set for the next week at the Lotte New York Palace Hotel on Tuesday at 9:00 a.m. ET.
Webcast Availability
TScan will offer webcasts of both the fireside chat and the presentation. These will be accessible in the “Events and Presentations” section of the Company’s website. Additionally, an archived replay of the webcasts will be available for 90 days after the events, allowing investors and interested individuals to catch up on any missed content.
Understanding TScan Therapeutics
TScan Therapeutics is leading the way in biotechnology innovation, particularly in TCR-engineered T cell therapies. The company is developing therapy candidates like TSC-100 and TSC-101, which target hematological malignancies and aim to prevent relapse after allogeneic hematopoietic cell transplantation. This research is part of the ALLOHA Phase 1 heme trial, representing a significant breakthrough for patients in need.
The Company’s Research and Development Goals
Moreover, TScan is actively working on TCR-T therapy candidates aimed at addressing various solid tumors. With a comprehensive ImmunoBank, the company has established a repository of therapeutic TCRs that target different markers associated with multiple HLA types. This allows TScan to provide customized multiplex TCR-T therapies tailored to individual cancer patients.
Expert Team at TScan
The dedicated leadership and team at TScan Therapeutics are committed to advancing cancer treatment. Their mission is to deliver innovative solutions by leveraging the latest scientific advancements. By harnessing the potential of engineered T cells, TScan aims to create effective therapies that can significantly improve cancer outcomes for patients.
Contact Information
For further information, interested parties can reach out to:
Heather Savelle
TScan Therapeutics, Inc.
VP, Investor Relations
857-399-9840
Email: hsavelle@tscan.com
Maghan Meyers
Argot Partners
212-600-1902
Email: TScan@argotpartners.com
Frequently Asked Questions
What is the focus of TScan Therapeutics?
TScan Therapeutics specializes in developing T cell receptor-engineered T cell therapies aimed at treating various cancers.
Which conferences will TScan participate in?
TScan will be present at the Morgan Stanley 22nd Annual Global Healthcare Conference and the H.C. Wainwright 26th Annual Global Investment Conference.
How can investors access TScan presentations?
Investors can view the presentations through webcasts available on the Company’s website, with replays archived for 90 days.
What are TScan’s lead therapy candidates?
The leading therapy candidates from TScan include TSC-100 and TSC-101, which are designed for hematologic malignancies.
Who should be contacted for investor relations inquiries?
For any investor relations inquiries, please contact Heather Savelle at TScan Therapeutics.
